COSMOS Pharmaceutical Toekomstige groei

Future criteriumcontroles 2/6

COSMOS Pharmaceutical zal naar verwachting groeien in winst en omzet met respectievelijk 5.9% en 6.6% per jaar. De winst per aandeel zal naar verwachting groeien met 6.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 10.7% zijn.

Belangrijke informatie

5.9%

Groei van de winst

6.2%

Groei van de winst per aandeel

Consumer Retailing winstgroei	12.8%
Inkomstengroei	6.6%
Toekomstig rendement op eigen vermogen	10.7%
Dekking van analisten	Good
Laatst bijgewerkt	11 Nov 2024

Recente toekomstige groei-updates

COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 17

Recent updates

COSMOS Pharmaceutical's (TSE:3349) Returns On Capital Not Reflecting Well On The Business

Nov 18

We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt

Sep 26

An Intrinsic Calculation For COSMOS Pharmaceutical Corporation (TSE:3349) Suggests It's 41% Undervalued

Aug 17

COSMOS Pharmaceutical (TSE:3349) Will Want To Turn Around Its Return Trends

Aug 01

Subdued Growth No Barrier To COSMOS Pharmaceutical Corporation's (TSE:3349) Price

Jun 28

We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt

Jun 10

COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Apr 17

Some Shareholders Feeling Restless Over COSMOS Pharmaceutical Corporation's (TSE:3349) P/E Ratio

Mar 16

Returns On Capital At COSMOS Pharmaceutical (TSE:3349) Paint A Concerning Picture

Feb 28

Winst- en omzetgroeiprognoses

TSE:3349 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (JPY Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
5/31/2027	1,208,961	30,781	16,450	N/A	12
5/31/2026	1,123,971	28,703	5,454	N/A	13
5/31/2025	1,039,241	26,882	2,339	N/A	13
8/31/2024	985,177	26,089	N/A	N/A	N/A
5/31/2024	964,989	24,454	-635	55,175	N/A
2/29/2024	936,706	24,871	N/A	N/A	N/A
11/30/2023	900,111	24,085	681	54,534	N/A
8/31/2023	863,228	23,824	N/A	N/A	N/A
5/31/2023	827,697	23,797	7,798	54,434	N/A
2/28/2023	802,831	22,983	N/A	N/A	N/A
11/30/2022	788,292	23,209	-3,655	41,973	N/A
8/31/2022	772,127	23,393	N/A	N/A	N/A
5/31/2022	755,414	23,155	-11,303	32,194	N/A
2/28/2022	743,612	22,030	N/A	N/A	N/A
11/30/2021	733,387	25,329	-5	35,596	N/A
8/31/2021	726,672	25,909	N/A	N/A	N/A
5/31/2021	726,424	27,156	1,811	27,875	N/A
2/28/2021	733,223	28,777	N/A	N/A	N/A
11/30/2020	723,309	25,736	28,882	50,935	N/A
8/31/2020	709,064	23,876	N/A	N/A	N/A
5/31/2020	684,403	21,435	39,513	65,461	N/A
2/29/2020	653,527	20,217	N/A	N/A	N/A
11/30/2019	638,034	18,951	10,653	38,209	N/A
8/31/2019	622,103	19,349	N/A	N/A	N/A
5/31/2019	611,137	19,185	5,339	34,379	N/A
2/28/2019	597,715	18,966	N/A	N/A	N/A
11/30/2018	585,536	18,857	1,302	30,947	N/A
8/31/2018	572,807	17,880	N/A	N/A	N/A
5/31/2018	557,999	17,633	N/A	32,586	N/A
2/28/2018	542,936	17,510	N/A	N/A	N/A
11/30/2017	526,523	17,313	N/A	35,488	N/A
8/31/2017	514,880	18,239	N/A	N/A	N/A
5/31/2017	502,732	18,215	N/A	36,938	N/A
2/28/2017	490,037	15,812	N/A	N/A	N/A
11/30/2016	477,739	14,981	N/A	34,300	N/A
8/31/2016	463,517	13,679	N/A	N/A	N/A
5/31/2016	447,273	12,435	N/A	30,986	N/A
2/29/2016	433,328	12,738	N/A	N/A	N/A
11/30/2015	423,817	12,474	N/A	22,426	N/A
8/31/2015	414,046	12,350	N/A	N/A	N/A
5/31/2015	408,466	11,694	N/A	19,454	N/A
2/28/2015	402,690	10,671	N/A	N/A	N/A
11/30/2014	392,527	10,286	N/A	26,260	N/A
8/31/2014	382,823	10,193	N/A	N/A	N/A
5/31/2014	371,825	10,600	N/A	25,962	N/A
2/28/2014	360,162	10,366	N/A	N/A	N/A
11/30/2013	349,966	9,975	N/A	17,627	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 3349 ( 5.9% per jaar) ligt boven de spaarquote ( 0.3% ).

Winst versus markt: De winst van 3349 ( 5.9% per jaar) zal naar verwachting langzamer groeien dan de markt JP ( 7.9% per jaar).

Hoge groeiwinsten: De winst van 3349 zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van 3349 ( 6.6% per jaar) zal naar verwachting sneller groeien dan de markt JP ( 4.2% per jaar).

Hoge groei-inkomsten: De omzet van 3349 ( 6.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 3349 zal naar verwachting over 3 jaar laag zijn ( 10.7 %).

COSMOS Pharmaceutical Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target increased by 7.0% to JP¥8,198

COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024

COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending May 31, 2024

COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending May 31, 2024

Cosmos Pharmaceutical Corporation Provides Earnings Forecast for the Fiscal Year Ending May 31, 2023

Recent updates

Upcoming dividend of JP¥32.50 per share

COSMOS Pharmaceutical's (TSE:3349) Returns On Capital Not Reflecting Well On The Business

COSMOS Pharmaceutical Corporation to Report Q2, 2025 Results on Jan 10, 2025

First quarter 2025 earnings: EPS exceeds analyst expectations

Price target increased by 7.0% to JP¥8,198

We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt

Final dividend of JP¥32.50 announced

An Intrinsic Calculation For COSMOS Pharmaceutical Corporation (TSE:3349) Suggests It's 41% Undervalued

COSMOS Pharmaceutical Corporation to Report Q1, 2025 Results on Oct 11, 2024

COSMOS Pharmaceutical (TSE:3349) Will Want To Turn Around Its Return Trends

Full year 2024 earnings: EPS misses analyst expectations

COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 20, 2024

COSMOS Pharmaceutical Corporation Announces Year-End Dividend for the Fiscal Year Ended May 31, 2024, Payable on August 1, 2024; Provides Second Quarter End and Year End Dividend Guidance for the Fiscal Year Ending May 31, 2025

Subdued Growth No Barrier To COSMOS Pharmaceutical Corporation's (TSE:3349) Price

We Think COSMOS Pharmaceutical (TSE:3349) Can Stay On Top Of Its Debt

Upcoming dividend of JP¥60.00 per share

COSMOS Pharmaceutical Corporation Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Some Shareholders Feeling Restless Over COSMOS Pharmaceutical Corporation's (TSE:3349) P/E Ratio

Returns On Capital At COSMOS Pharmaceutical (TSE:3349) Paint A Concerning Picture

COSMOS Pharmaceutical Corporation to Report Q3, 2024 Results on Apr 12, 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending May 31, 2024

Upcoming dividend of JP¥60.00 per share at 0.8% yield

COSMOS Pharmaceutical Corporation to Report Q2, 2024 Results on Jan 12, 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending May 31, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

COSMOS Pharmaceutical Corporation to Report Q1, 2024 Results on Oct 11, 2023

Full year 2023 earnings: EPS exceeds analyst expectations

COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 22, 2023

COSMOS Pharmaceutical Corporation Provides Consolidated Earnings Guidance for the First Half and Full Year of Fiscal Year Ending May 31, 2024

Upcoming dividend of JP¥42.50 per share at 0.6% yield

Third quarter 2023 earnings: EPS misses analyst expectations

COSMOS Pharmaceutical Corporation to Report Q3, 2023 Results on Apr 10, 2023

Second quarter 2023 earnings: EPS misses analyst expectations

Cosmos Pharmaceutical Corporation Provides Earnings Forecast for the Fiscal Year Ending May 31, 2023

Upcoming dividend of JP¥42.50 per share

No independent directors

COSMOS Pharmaceutical Corporation to Report Q2, 2023 Results on Jan 12, 2023

First quarter 2023 earnings: EPS exceeds analyst expectations

COSMOS Pharmaceutical Corporation Provides Dividend Guidance for the Second Quarter-End and Full Year of Fiscal Year Ending May 31, 2023

Full year 2022 earnings: EPS exceeds analyst expectations

COSMOS Pharmaceutical Corporation to Report Q1, 2023 Results on Oct 11, 2022

COSMOS Pharmaceutical Corporation, Annual General Meeting, Aug 23, 2022

Full year 2022 earnings: EPS exceeds analyst expectations

COSMOS Pharmaceutical Corporation Announces Dividend Guidance for the Second Quarter and Year End of Fiscal Year Ending May 31, 2023

Price target decreased to JP¥14,800

Upcoming dividend of JP¥40.00 per share

COSMOS Pharmaceutical Corporation to Report Fiscal Year 2022 Results on Jul 11, 2022

No independent directors

Third quarter 2022 earnings: EPS misses analyst expectations

COSMOS Pharmaceutical Corporation to Report Q3, 2022 Results on Apr 11, 2022

Second quarter 2022 earnings: EPS misses analyst expectations

Upcoming dividend of JP¥40.00 per share

First quarter 2022 earnings released: EPS JP¥158 (vs JP¥189 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥686 (vs JP¥541 in FY 2020)

Cosmos Pharmaceutical Corp to Be Deleted from Other OTC

Upcoming dividend of JP¥27.50 per share

Third quarter 2021 earnings released: EPS JP¥215 (vs JP¥138 in 3Q 2020)

Investor sentiment improved over the past week

COSMOS Pharmaceutical Corporation to Report Q3, 2021 Results on Apr 12, 2021

New 90-day low: JP¥15,820

Earnings beat expectations, revenue disappoints

Earnings beat expectations, revenue disappoints

Second quarter 2021 earnings released: EPS JP¥141

New 90-day low: JP¥16,110

New 90-day low: JP¥16,720

COSMOS Pharmaceutical Corporation to Report Q2, 2021 Results on Jan 12, 2021